NCT06744335

Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)

Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,282 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan

Detailed description

Primary endpoints: The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR \<60 ml/min/1.73 m2 (CFR categories C3a-C5). Secondary endpoints: The following secondary endpoints will be evaluated in all patients with AH and markers of CKD included in the study (Full Analysis Sampling - FAS) (Secondary Aim 1) and in the subgroup of patients with a diagnosis of CKD confirmed during the study (Modified Full Analysis Sampling - mFAS), i.e., at Visit 1 or Visit 2 (Secondary Aim 2):

Conditions

• Rate of CKD Diagnosis in Patients With AH and CKD Markers
• Demographic and Clinical Characteristics for Those Patients
• Routine Therapy Before and After the Diagnosis of CKD

Timeline

• Start date: 2025-01-20
• Primary completion: 2026-08-20
• Completion: 2026-08-20
• First posted: 2024-12-20
• Last updated: 2026-04-08

Locations

29 sites across 1 country: Kazakhstan